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Abstract
Intracerebral hemorrhage remains a challenging worldwide clinical problem with no proven
treatments. In the acute phase of the illness, there has been some controversy regarding the
appropriate management of elevated blood pressure. Recently published and ongoing clinical trials are
beginning to shed some light on appropriate blood pressure management in acute intracerebral
hemorrhage. This brief review focuses on these trials. In the next few years, it is hoped that clinical
uncertainty regarding this issue will be obviated after completion of these trials.
Introduction and context
Spontaneousintracerebralhemorrhage(ICH)occursinan
estimated2millionpeopleworldwideeachyear[1,2].ICH
has a 30-day mortality of 32-50% [3,4] and only 20% of
survivors are functionally independent at 6 months [5].
NoproventherapiesexistforICH.Elevatedbloodpressure
at presentation is one of the factors that has been
consistently associated with worse outcomes in ICH
[6-8]. It remains unclear whether elevated blood pressure
is an epiphenomenon of severe ICH or an independent
risk factor for poor outcome. The rate of blood pressure
decline in the first 24 hours after ICH has also been
associated with poor outcomes [9]. Thus, there is clinical
concern that markedly elevated blood pressure may
contribute to early hematoma expansion, while overly
aggressive blood pressure reduction may compromise
cerebralbloodflowtoperihematomalregionsofthebrain.
Since phase III clinical trial data are lacking, recent
guidelines do not have Class I recommendations for
blood pressure reduction in ICH [3,10]. The European
Stroke Initiative Guidelines recommend a target mean
arterial pressure (MAP) of 125 mmHg in patients with
a history of hypertension and 110 mmHg in those
without a history of hypertension [10]. The American
Heart Association Guidelines recommend keeping
MAP at less than 130 mmHg while maintaining
cerebral perfusion pressure at more than 60 mmHg
in patients with elevated intracranial pressure. A goal
MAP of 110 mmHg is recommended for patients
without elevated intracranial pressure [3]. This review
focuses on recently published and ongoing clinical
trials that may directly impact blood pressure manage-
ment in acute ICH within the next few years.
Recent advances
The Intensive Blood Pressure Reduction in Acute
Cerebral Haemorrhage Trial (INTERACT) is the largest
study published to date on blood pressure management
in acute ICH [11]. INTERACT enrolled ICH patients
diagnosed by computed tomography within 6 hours
of symptom onset with elevated systolic blood pres-
sure (150-220 mmHg). A total of 404 patients were
randomized to intensive blood pressure reduction
(target systolic blood pressure 140 mmHg; n = 203) or
standard guideline-based management of blood pressure
(target systolic blood pressure 180 mmHg; n = 201). The
primary endpoint was change in hematoma volume at
24 hours. Safety and clinical outcomes were assessed for
up to 90 days.
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Published: 21 October 2010From randomization to 1 hour, mean systolic blood
pressure was 153 mmHg in the intensive group and
167 mmHg in the guideline group (P <0.0001); from
1 hour to 24 hours, it was 146 mmHg in the intensive
group and 157 mmHg in the guideline group
(P<0.0001). The relative risk of hematoma expansion
was 36% lower (95% confidence interval 0-59%,
P = 0.05) in the intensive group than in the guideline
group. Intensive blood pressure reduction did not alter
the risks of adverse events or outcomes at 90 days. The
authors concluded that early blood pressure reduction
is clinically feasible, well tolerated, and may reduce
hematoma expansion in ICH [11].
The Antihypertensive Treatment of Acute Cerebral
Hemorrhage (ATACH) trial is another recently published
study of blood pressure management in acute ICH [12].
The objective of ATACH was to determine the safety
and feasibility of three levels of systolic blood pressure
reduction within 6 hours of symptom onset in ICH
patients with initial systolic blood pressure greater than or
equal to 170 mmHg. Intravenous nicardipine was infused
for a target systolic blood pressure of 170-200 mmHg in
the first cohort of patients (n = 18), 140-170 mmHg in
the second cohort (n = 20) and 110-140 mmHg in the
third cohort (n = 22). Primary outcomes were feasibility
of treatment, neurological deterioration within 24 hours,
and serious adverse events within 72 hours. No significant
adverse events above the pre-specified safety stopping
points were observed [12].
Implications for clinical practice
The INTERACT study provides the best available
evidence to date for aggressive early blood pressure
reduction in ICH. Overall, INTERACT suggests that for
patients similar in clinical characteristics to those
enrolled in the study, reducing systolic blood pressure
to 140 mmHg is safe and may reduce risk of hematoma
expansion. The Second Intensive Blood Pressure Reduc-
tion in Acute Cerebral Haemorrhage Trial (INTERACT2)
is the phase III follow-up study to INTERACT. An
estimated 2800 patients will be enrolled by the planned
December 2011 study completion date [13]. This study
may provide clinicians with an answer regarding an age-
old clinical question in the management of acute ICH.
The ATACH investigators are also proceeding with a
phase III follow-up study, although recruitment has not
begun for that study. It should be noted that INTERACT
excluded patients with the severest injury (Glasgow
Coma Score [GCS] 3-5), and enrolled patients had
mean ICH volumes of 12 mL (guideline) and 14 mL
(intensive). INTERACT was also not powered to detect
clinical outcomes. ATACH included only patients with a
GCS of greater than 8 and hematoma volume of less than
60 mL. Therefore, the findings in these trials may not be
applicable to all ICH patients.
In summary, while many clinical questions remain
regarding the acute management of ICH, recent and
ongoing trials are shedding light on the management of
blood pressure in acute ICH. It is anticipated that Class I
recommendations for blood pressure management in
ICH will be generated by ongoing trials.
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